The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development
Abstract
Introduction: Over a decade of research and development culminated in the 2017 United States (US) Food and Drug Administration (FDA) approval of voretigene neparvovec-rzyl (VN) for RPE65 mutation-associated inherited retinal disease (IRD), the first approved gene therapy for a hereditary genetic disease in the US, and the first and only pharmacologic treatment for an IRD.Areas covered: VN serves as a model for ocular gene therapy development, while RPE65 mutation-associated IRD serves as an example of a well-suited candidate disorder. This review also discusses development considerations for viral vector gene augmentation, and, studies that led to VN’s FDA approval. Subretinal injection of VN resulted in improved performance on the novel multi-luminance mobility test (MLMT), light sensitivity, and visual fields in patients with RPE65 mutation-associated IRD, which predominantly impairs rod function. Additionally, the dosage, administration technique, pharmacokinetics, and safety data of VN are reviewed.Expert Opinion: As a model for development, special challenges associated with the introduction of this first ocular gene therapy include limited genetic testing in clinical practice, novel surgical complexity of ocular gene therapy administration, new functional vision endpoints, as well as unique development, launch, and reimbursement considerations associated with orphan therapies and one-time gene therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Luxturna from Spark Therapeutics, for the treatment of Leber congenital amaurosis (LCA) type 2, showed safety and efficacy in phase I/II clinical trials11–13 and was the first US Food and Drug Administration (FDA)-approved gene therapy (2017) for an inherited disorder in the United States.14,15”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [13]
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Research works printed but not linked: 11
- Wenkel H, 1998, Invest Ophthalmol Vis Sci, 39, 1823
- Chung DC, 2018, Am J Ophthalmol
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Carter PJ, 2000, Int J Mol Med, 6, 17
- United States Secturities and Exchange Commission, Form 10-Q, For the quarterly period ended September 30, 2018, spark therapeutics; 2018.
- Drack AV, 2019, JAAPOS, 23, e7
- Li Q, 2008, Mol Vis, 14, 1760
- Yiu G, 2020, Mol Ther, 16
- Mahajan VB, 2018, American academy of ophthalmology
- Yang U, 2019, JAMA Ophthalmol, 1
- Brown GC, 2005, Trans Am Ophthalmol Soc, 103, 173
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Endpoints for clinical trials in ophthalmology
Schmetterer, L. F., Scholl, H. P. N., Garhöfer, G., Janeschitz‐Kriegl, L., Corvi, F., Sadda, S. R., & Medeiros, F. A. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101160 · Cited by 96
Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa
Meng, D., Ragi, S. D., & Tsang, S. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.012 · Cited by 82
Precision genome editing in the eye
Suh, S., Choi, E. H., Raguram, A., Liu, D. R., & Palczewski, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210104119 · Cited by 59
Rational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53
Metadata
- Authors
- Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A.
- Affiliations
- Midwest Eye Institute (US)
- Retina Associates Ltd, Elmhurst, IL, USA
- University of Miami (US)
- University of Southern California (US)
- Corresponding author
- Ciulla, Thomas A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-03-25
- Volume
- 20
- Issue
- 6
- Pages
- 565-578
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W3009064404
- Cited by
- 59
- References
- 57
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 18 · 2020: 5
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- RPE65 mutations, inherited retinal disease, ocular gene therapy, adeno-associated virus vectors, subretinal injection, rod photoreceptor function, visual field, pharmacokinetics, gene therapy safety, FDA approval
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Clinical Trials as Topic, Conjunctival Diseases, Dose-Response Relationship, Drug, Genetic Vectors, Humans, Retinal Diseases, Tears, Genetic Therapy, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. https://app.cochat.ai/papers/10.1080/14712598.2020.1740676
- The paper
- Ciulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020). Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1740676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.